CLRB.OQ
Latest Trade
2.02USDChange
-0.03(-1.46%)Volume
303,817Today's Range
-
2.0852 Week Range
-
3.31As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 2.05 |
|---|---|
Open | 2.07 |
Volume | 303,817 |
3M AVG Volume | 39.74 |
Today's High | 2.08 |
Today's Low | 1.99 |
52 Week High | 3.31 |
52 Week Low | 1.01 |
Shares Out (MIL) | 27.26 |
Market Cap (MIL) | 55.88 |
Forward P/E | -2.44 |
Dividend (Yield %) | -- |
Cellectar Reports Q3 Loss Per Share Of $0.15
Cellectar Q2 Loss Per Share $0.26
Lincoln Park Capital Fund Reports 8.92% Passive Stake In Cellectar Biosciences, Inc As Of July 11
Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. The Company’s research and development program is based on its PDC cancer-targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates, including radiotherapeutic and chemotherapeutic PDC's. Its PDC therapeutic, CLR 131 is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells. The Company’s product pipeline also includes one preclinical PDC chemotherapeutic program (CLR 1900). The CLR 1900 Series is targeted for solid tumors with a payload that inhibits mitosis a validated pathway for treating cancers.
Industry
Biotechnology & Drugs
Executive Leadership
Douglas J. Swirsky
Independent Chairman of the Board
James V. Caruso
President, Chief Executive Officer, Director
Dov Elefant
Chief Financial Officer, Vice President
John E. Friend
Vice President, Chief Medical Officer
Jarrod Longcor
Chief Business Officer
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | -- |
Price To Book (MRQ) | 3.65 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 1.13 |
LT Debt To Equity (MRQ) | 1.13 |
Return on Investment (TTM) | -101.01 |
Return on Equity (TTM) | -81.74 |
* CELLECTAR TO BE GRANTED EU PATENT FOR PHOSPHOLIPID ETHER (PLE) ANALOGS AS CANCER-TARGETING DRUG VEHICLES Source text for Eikon: Further company coverage:
* AIGH CAPITAL MANAGEMENT, LLC. REPORTS A PASSIVE STAKE OF 6.52% IN CELLECTAR BIOSCIENCES AS OF JUNE 3 - SEC FILING Source text: (https://bit.ly/2ARNezM) Further company coverage:
* CELLECTAR BIOSCIENCES ANNOUNCES PRICING OF $20 MILLION UNDERWRITTEN PUBLIC OFFERING
* CELLECTAR GRANTED SME STATUS BY THE EUROPEAN MEDICINES AGENCY Source text for Eikon: Further company coverage:
* CELLECTAR RECEIVES FDA FAST TRACK DESIGNATION FOR CLR 131 IN LYMPHOPLASMACYTIC LYMPHOMA/WALDENSTROM’S MACROGLOBULINEMIA Source text for Eikon: Further company coverage:
* CELLECTAR BIOSCIENCES - OFFERING 11.9 MILLION COMMON SHARES, PRE-FUNDED WARRANTS TO PURCHASE COMMON SHARES, WARRANTS TO PURCHASE 5.95 MILLION COMMON SHARES Source text: [https://bit.ly/2zRu4JN] Further company coverage: (Reuters.Briefs@thomsonreuters.com)
* CELLECTAR BIOSCIENCES INC FILES FOR COMMON STOCK OFFERING OF UP TO $17.5 MILLION - SEC FILING Source text for Eikon: https://bit.ly/2YXM4wP Further company coverage:
* CELLECTAR REPORTS FINANCIAL RESULTS FOR YEAR ENDED DECEMBER 31, 2019 AND PROVIDES A CORPORATE UPDATE
* CELLECTAR GRANTED ORPHAN DRUG DESIGNATION FOR CLR 131 TO TREAT RHABDOMYOSARCOMA Source text for Eikon: Further company coverage:
* CELLECTAR BIOSCIENCES APPOINTS BRIAN M. POSNER AS CHIEF FINANCIAL OFFICER
* CELLECTAR GRANTED SEMINAL U.S. PATENT FOR PHOSPHOLIPID-ETHER ANALOGS AS CANCER-TARGETING DRUG VEHICLES Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)
* CELLECTAR REPORTS 2017 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE
* CELLECTAR BIOSCIENCES GRANTED ORPHAN DRUG DESIGNATION FOR CLR 131 TO TREAT NEUROBLASTOMA
* CELLECTAR RECEIVES USPTO NOTICE OF ALLOWANCE FOR PATENT COVERING USE OF CLR 131 IN MULTIPLE MYELOMA Source text for Eikon: Further company coverage:
* CELLECTAR BIOSCIENCES - ON JAN 3, NOTIFIED AFFECTED EMPLOYEES OF ITS PLAN TO REDUCE ITS WORKFORCE BY 6 POSITIONS -SEC FILING
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.